IRVINE, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans on reporting its second quarter 2016 financial results on Thursday, August 11, after the close of the financial markets.
ChromaDex management will host an investor conference call to discuss the quarterly results and provide a general business update on Thursday, August 11, at 4:30pm ET.
Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows:
|U.S. Toll-Free Number:||(866) 327-8118|
|International Dial-In Number:||(678) 509-7526|
The webcast replay will be available after the completion of the call on the Investor Relations section of the Company website, www.chromadex.com.
The earnings press release, and its accompanying financial exhibits, will be available on the Investor Relations section of the Company website, www.chromadex.com.
ChromaDex, a leading provider of science-backed technologies and analytical services for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, connects the knowledge and key relationships within its complementary businesses to discover, acquire, develop, and commercialize patented and proprietary health related innovations. The company utilizes their in-house chemistry, regulatory and safety consulting expertise (Spherix Consulting) to develop revolutionary ingredients such as NIAGEN®, the only commercially available form of nature-identical nicotinamide riboside; pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal; IMMULINA™, a spirulina extract; and anthocyanins derived from a domestically-produced, water-extracted, non-GMO, hybrid purple corn. ChromaDex technologies drive advancements in health and wellness for the dietary supplement, sports nutrition, pharmaceutical, food and beverage and skin care industries. To learn more about ChromaDex, please visit www.ChromaDex.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in ChromaDex's business. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended January 2, 2016, ChromaDex's Quarter Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
ChromaDex Company Contact: Andrew Johnson Director of Investor Relations 949-419-0288 email@example.com